Sugi Predict

Sugi Predict / Compounds / SCHEMBL950791

SCHEMBL950791

SCHEMBL950791

CCC(=O)N1CC[CH]CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CHRNB2 P17787 3/20 0.42
▸ CHRNA3 P32297 3/20 0.42
▸ CHRNA4 P43681 3/20 0.42
▸ CHRNB3 Q05901 1/20 0.42
▸ CHRNA6 Q15825 1/20 0.42
▸ EPHX2 P34913 5/20 0.42
▸ CHRNB4 P30926 2/20 0.41
▸ CHRNA7 P36544 2/20 0.41
▸ OPRM1 P35372 1/20 0.40
▸ DRD3 P35462 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301437 0.86 — —
SCHEMBL25630651 0.86 BLM (0.48) BLMALDH1A1MEN1TSHRKMT2A
SCHEMBL293379 0.82 L3MBTL1 (0.48) ALDH1A1MEN1KMT2ACHRNB2CHRNA3
SCHEMBL20756575 0.82 BLM (0.57) BLMALDH1A1MEN1TSHRKMT2A
SCHEMBL2739418 0.82 BLM (0.57) BLMALDH1A1MEN1TSHRKMT2A
SCHEMBL180620 0.82 — —
SCHEMBL293140 0.79 L3MBTL1 (0.60) MEN1KMT2AL3MBTL1NPC1MAPT
SCHEMBL196766 0.78 AKR1C3 (0.41) ALDH1A1MEN1TSHRKMT2AL3MBTL1
SCHEMBL805446 0.77 — —
SCHEMBL299507 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200179376-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYOWA KIRIN CO., LTD. (JP) 2020-06-11 — — US claimed
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-05-31 — — US claimed
EP-3294729-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-03-21 — — EP claimed
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 — — US claimed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 — — US claimed
WO-2016180536-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 — — WO claimed
US-20150352106-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYOWA KIRIN CO., LTD. (JP) 2015-12-10 — — US claimed
WO-2015123453-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-20 — — WO claimed
EP-2570411-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING KYNURENINE PRODUCTION INHIBITORY ACTIVITY Kyowa Hakko Kirin Co., Ltd. (JP) 2013-03-20 — — EP claimed
US-20130065905-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-03-14 — — US claimed
EP-1495020-A1 N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2005-01-12 — — EP claimed
US-20040116439-A1 Serine protease inhibitors TULARIK LIMITED (GB) 2004-06-17 — — US claimed
US-20030216403-A1 Serine protease inhibitors TULARIK LIMITED (GB) 2003-11-20 — — US claimed
WO-2003082863-A1 N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 — — WO claimed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 — — EP claimed
EP-1294691-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-03-26 — — EP claimed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 — — EP claimed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 — — WO claimed
WO-2001096305-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-12-20 — — WO claimed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200179376-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYNU, KMO, IDO1 BLM 4498/4885ALDH1A1 2390/4885MEN1 1254/4885
US-20150352106-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYNU, KMO, IDO1 BLM 4498/4885ALDH1A1 2390/4885MEN1 1254/4885
US-20030216403-A1 Serine protease inhibitors SERPINB1, SERPINE1, PRSS1 BLM 2390/4885ALDH1A1 1913/4885MEN1 2414/4885
US-20130065905-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE KYNU, KMO, IDO1 BLM 4516/4885ALDH1A1 2415/4885MEN1 1313/4885
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS JAK1, JAK2, JAK3 BLM 4585/4885ALDH1A1 2112/4885MEN1 2714/4885
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES BRCA1, NQO2, NQO1 BLM 63/4885ALDH1A1 1674/4885MEN1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.